Astellas Pharma Statistics

Total Valuation

Astellas Pharma has a market cap or net worth of 17.12 billion. The enterprise value is 21.25 billion.

Market Cap	17.12B
Enterprise Value	21.25B

Important Dates

The next estimated earnings date is Friday, January 31, 2025.

Earnings Date	Jan 31, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	-0.78%
Shares Change (QoQ)	+0.11%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	1.79B

Valuation Ratios

The trailing PE ratio is 44.79.

PE Ratio	44.79
Forward PE	n/a
PS Ratio	n/a
PB Ratio	n/a
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 9.06, with an EV/FCF ratio of 19.87.

EV / Earnings	55.61
EV / Sales	1.86
EV / EBITDA	9.06
EV / EBIT	19.60
EV / FCF	19.87

Financial Position

The company has a current ratio of 1.10, with a Debt / Equity ratio of 0.61.

Current Ratio	1.10
Quick Ratio	0.79
Debt / Equity	0.61
Debt / EBITDA	2.56
Debt / FCF	6.11
Interest Coverage	14.19

Financial Efficiency

Return on equity (ROE) is 3.45% and return on invested capital (ROIC) is 4.25%.

Return on Equity (ROE)	3.45%
Return on Assets (ROA)	3.03%
Return on Capital (ROIC)	4.25%
Revenue Per Employee	838,407
Profits Per Employee	25,900
Employee Count	14,754
Asset Turnover	0.51
Inventory Turnover	1.36

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -17.99% in the last 52 weeks. The beta is 0.22, so Astellas Pharma's price volatility has been lower than the market average.

Beta (5Y)	0.22
52-Week Price Change	-17.99%
50-Day Moving Average	10.09
200-Day Moving Average	10.64
Relative Strength Index (RSI)	34.26
Average Volume (20 Days)	309,897

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Astellas Pharma had revenue of 12.37 billion and earned 382.13 million in profits. Earnings per share was 0.21.

Revenue	12.37B
Gross Profit	10.12B
Operating Income	1.19B
Pretax Income	402.70M
Net Income	382.13M
EBITDA	2.55B
EBIT	1.19B
Earnings Per Share (EPS)	0.21

Full Income Statement

Balance Sheet

The company has 2.05 billion in cash and 6.53 billion in debt, giving a net cash position of -4.49 billion.

Cash & Cash Equivalents	2.05B
Total Debt	6.53B
Net Cash	-4.49B
Net Cash Per Share	n/a
Equity (Book Value)	10.68B
Book Value Per Share	5.97
Working Capital	765.40M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 1.40 billion and capital expenditures -332.26 million, giving a free cash flow of 1.07 billion.

Operating Cash Flow	1.40B
Capital Expenditures	-332.26M
Free Cash Flow	1.07B
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 81.78%, with operating and profit margins of 9.59% and 3.09%.

Gross Margin	81.78%
Operating Margin	9.59%
Pretax Margin	3.26%
Profit Margin	3.09%
EBITDA Margin	20.65%
EBIT Margin	9.59%
FCF Margin	8.65%

Dividends & Yields

Astellas Pharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	229.26%
Buyback Yield	0.78%
Shareholder Yield	0.78%
Earnings Yield	n/a
FCF Yield	n/a

Stock Splits

The last stock split was on April 2, 2014. It was a forward split with a ratio of 1.25.

Last Split Date	Apr 2, 2014
Split Type	Forward
Split Ratio	1.25

Scores

Astellas Pharma has an Altman Z-Score of 1.98. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	1.98
Piotroski F-Score	n/a